Table 1.
Efficacy data of the model
| Therapy | PASI ≥ 75 | Source |
|---|---|---|
| Dovobet | 19.7% | Langley et al43 Patients adherent to ointment treatment (4 weeks) 98.41% |
| Phototherapy | 76.6% | Bottomley et al44 |
| Acitretin | 43.0% | Geiger et al45 |
| Methotrexate | 35.5% | Saurat et al46 |
| Cyclosporine | 33.0% | Schmitt et al47 |
| Weighted mean efficacy | 36% | |
| Infliximab | 80.0% | Reich et al48 |
| Adalimumab | 58.0% | |
| Etanercept 50 mg | 52.0% | |
| Etanercept 25 mg | 39.0% | |
| Ustekinumab 45 mg | 39.0% | |
| Weighted mean efficacy | 54.0% | |
| Relapse probability with topical drugs | 41.8% | Naldi et al33 |
| Relapse probability with phototherapy | 11.6% | Assumption of the authors |
Abbreviation: PASI, Psoriasis Area Severity Index.